<DOC>
	<DOCNO>NCT00004055</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness topotecan , paclitaxel , filgrastim treat patient previously untreated extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Topotecan , Paclitaxel , Filgrastim Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate oral topotecan paclitaxel term toxicity complete partial response rate patient previously untreated extensive stage small cell lung cancer . II . Determine preliminary estimate survival patient population response regimen . OUTLINE : Patients receive oral topotecan day 1-5 follow paclitaxel IV 3 hour day 5 . Beginning 24-48 hour chemotherapy , patient receive filgrastim ( G-CSF ) subcutaneously daily 10 day blood count recover . Treatment repeat every 4 week 6 course absence disease progression . Patients develop CNS progressive disease receive whole brain radiotherapy continue study treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm previously untreated small cell lung cancer No mixed histology Extensive disease Metastatic disease outside chest Contralateral supraclavicular node contralateral hilar node outside single radiation port OR Cytologically proven malignant pleural effusion Measurable evaluable disease No untreated CNS metastasis CNS metastases previously treat whole brain radiotherapy allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : AST great 5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN Total bilirubin great 1.5 time ULN OR Direct bilirubin normal Renal : Creatinine great ULN OR Creatinine clearance least 50 mL/min Cardiovascular : No uncontrolled angina pectoris No congestive heart failure within past 3 month , unless ejection fraction great 40 % No uncontrolled arrhythmias No myocardial infarction within past 3 month Other : No significant infection No hypersensitivity E. coli derivatives No malignancy within past 3 year except nonmelanoma skin cancer , carcinoma situ cervix , localized prostate cancer Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 10 year since prior chemotherapy No prior nitrosourea base chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 10 year since prior thoracic radiotherapy No 3 fraction prior thoracic radiotherapy superior vena cava syndrome Prior palliative radiotherapy except chest allow No prior radiotherapy least 20 % bone marrow No concurrent radiotherapy ( include thoracic ) , except whole brain radiotherapy CNS progression Surgery : At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>